New potential treatment pathway against diffuse large large B-cell lymphoma

Researchers from Weill Cornell Medical College believe they have discovered a new pathway for treatment of patients with diffuse large B-cell lymphoma (DLBCL), the most commonly diagnosed subtype of non-Hodgkin's lymphoma.

Current standard treatment for DLBCL includes combination chemotherapy in the form of R-CHOP followed by radiation, but this treatment carries a significant toxicity profile along with tissue damage and sometimes severe side effects. A more targeted treatment is therefore in order.

Patients with DLBCL often have tumors that express the BLC-6 gene mutation, offering these researchers a potential treatment pathway by using an inhibitor known as RI-BPI along with a histone deacetylases (HDAC) inhibitor or with a heat shock protein (Hsp90) inhibitor. When researchers exploited this pathway, they were able to stifle tumor activity and even wipe out any signs of cancer.

NOTE: These results are derived from pre-clinical (mouse model) trials and should therefore be considered accordingly.

TREATMENT TYPE(S)

Targeted treatment

WHERE WAS THIS STUDY PUBLISHED?

Journal of Clinical Investigation